Active surveillance for prostate cancer: For whom?

Journal of Clinical Oncology

Volumn 23, Issue 32, 2005, Pages 8165-8169

  Klotz, Laurence ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ALGORITHM; BRACHYTHERAPY; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; EXTERNAL BEAM RADIOTHERAPY; GLEASON SCORE; HEALTH SURVEY; HUMAN; MORTALITY; PALLIATIVE THERAPY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; TREATMENT PLANNING; FORECASTING; MALE; METABOLISM; PROSTATE TUMOR; RISK FACTOR;

FORECASTING; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 32044460994     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.03.3134     Document Type: Review

References (29)

1. Schroder FH, Raaijmakers R, Postma R, et al: 4-year prostate specific antigen progression and diagnosis of prostate cancer in the European randomized study of screening for prostate cancer, section Rotterdam. J Urol 174:489-494, 2005
2. Thompson IM, Pauler DK, Goodman PJ, et al: Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 350:2239-2246, 2004 [erratum in N Engl J Med 351:1470, 2004]
3. Stamey TA, Caldwell M, McNeal JE, et al: The prostate specific antigen era in the United States is over for prostate cancer: What happened in the last 20 years? J Urol 172:1297-1301, 2004
4. Harlan SR, Cooperberg MR, Elkin EP, et al: Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: Results from CaPSURE. J Urol 170:1804-1807, 2003
5. Albertsen PC, Hanley JA, Fine J: 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293:2095-2101, 2005
6. Bill-Axelson A, Holmberg L, Ruutu M, et al: Scandinavian Prostate Cancer Group Study No 4: Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 352:1977-1984, 2005
7. Pound CR, Partin AW, Eisenberger MA, et al: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281:1591-1597, 1999
8. Johansson JE, Holmberg L, Johansson S, et al: Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA 277:467-471, 1997 [erratum in JAMA 278:206, 1997]
9. D'Amico AV, Cote K, Loffredo M, et al: Determinants of prostate cancer specific survival following radiation therapy during the prostate specific antigen era. J Urol 170:542-546, 2003
10. Lukka H, Warde P, Pickles T, et al: Canadian GU Radiation Oncologist Group. Controversies in prostate cancer radiotherapy: Consensus development. Can J Urol 8:1314-1322, 2001
11. Hanash KA, Utz DC, Cook EN, et al: Carcinoma of the prostate: A 15 year follow-up. J Urol 107:450-453, 1972
12. Cook GB, Watson FR: Twenty nodules of prostate cancer not treated by total prostatectomy. J Urol 100:672-674, 1968
13. Barnes R, Hirst A, Rosenquist R: Early carcinoma of the prostate: Comparison of stages A and B. J Urol 115:404-405, 1976
14. Lerner SP, Seale-Hawkins C, Carlton CE, et al: The risk of dying of prostate cancer in patients with clinically localized disease. J Urol 146:1040-1045, 1991
15. Handley R, Carr TW, Travis D, et al: Deferred treatment for prostate cancer. Br J Urol 62:249-253, 1988
16. Adolfsson J, Carstensen J, Lowhagen T: Deferred treatment in clinically localized prostate carcinoma. Br J Urol 69:183-187, 1992
17. D'Amico AV, Chen MH, Roehl KA, et al: Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 351:125-135, 2004
18. Bastian PJ, Mangold LA, Epstein JI, et al: Characteristics of insignificant clinical Tie prostate tumors: A contemporary analysis. Cancer 101:2001-2005, 2004
19. Epstein JI, Chan DW, Sokoll LJ, et al: Nonpalpable stage T1c prostate cancer: Prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol 160:2407-2411, 1998
20. Irwin MB, Trapasso JG: Identification of insignificant prostate cancers: Analysis of preoperative parameters. Urology 44:862-867, 1994
21. Cupp MR, Bostwick DG, Myers RP, et al: The volume of prostate cancer in the biopsy specimen cannot reliably predict the quantity of cancer in the radical prostatectomy specimen on an individual basis. J Urol 153:1543-1548, 1995
22. Goto Y, Ohori M, Scardino PT: Use of systematic biopsy results to predict pathologic stage in patients with clinically localized prostate cancer: A preliminary report. Int J Urol 5:337-342, 1998
23. Noguchi M, Stamey TA, McNeal JE, et al: Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: Lack of prediction of tumor significance for men with nonpalpable prostate cancer. J Urol 166:104-109, 2001
24. Augustin H, Hammerer PG, Graefen M, et al: Insignificant prostate cancer in radical prostatectomy specimen: Time trends and preoperative prediction. Eur Urol 43:455-460, 2003
25. Anast JW, Andriole GL, Bismar TA, et al: Relating biopsy and clinical variables to radical prostatectomy findings: Can insignificant and advanced prostate cancer be predicted in a screening population? Urology 64:544-550, 2004
26. Choo R, DeBoer G, Klotz L, et al: PSA doubling time of prostate carcinoma managed with watchful observation alone. Int J Radiat Oncol Biol Phys 50:615-620, 2001
27. Choo R, Klotz L, Danjoux C, et al: Feasibility study of watchful waiting for localized low to intermediate grade prostate cancer with selective delayed intervention based on PSA, histologic, and/or clinical progression. J Urol 167:1664-1669, 2002
28. Klotz L: Active surveillance with selective delayed intervention: Using natural history to guide treatment in good risk prostate cancer. J Urol 172:548-550, 2004
29. Steineck G, Helgesen F, Adolfsson J, et al: Scandinavian Prostatic Cancer Group Study No 4: Quality of life after radical prostatectomy or watchful waiting. N Engl J Med 347:790-796, 2002